🎉 Celebrate #LaborDay with us and get ready for NCM Boston! The first 10 people to use the code 'NCM LABOR DAY' will snag a FREE ticket! We've also curated some must-see talks, check them out below.👇 Single-Cell Research Don’t miss Megan Noonan’s talk on "Nanopore transcriptomics to identify alternative splicing in renal tubule cells" and Benjamin Reiner on how "Ketamine and ECT alter prefrontal cortex cell type-specific transcriptomes." Cancer Research Explore new frontiers with Mathilde Filser on "Redefining cancer characterization via nanopore sequencing" and Stephanie Chrysanthou’s work on "Detecting germline alterations in homologous recombination repair genes." Rare Disease and clinical research Shilpa Kobren will discuss "Long-read sequencing for tough cases in the Undiagnosed Diseases Network." Plus, hear from Wanqing Shao and Svetlana Madjunkova on sequencing's role in pediatric rare disease and reproductive care respectively. Infectious disease research Samuel Shelburne will discuss "Nanopore sequencing to trace hospital infection transmission," while Ela Sauerborn will reveal "Hidden antibiotic resistance through real-time genomics." Accessibility High schooler Noah Bryan asks, "Is the water safe? The rapid test is the missing link!" Also, don’t miss Laura Kamenetzky on "Expanding long-read sequencing in southern South America. Don’t miss these groundbreaking talks at NCM Boston! Secure your ticket today and check out the rest of the agenda here: https://bit.ly/4dRyxKD #nanoporeconf
Oxford Nanopore Technologies
生物技术研究
Our goal is to enable the analysis of anything, by anyone, anywhere.
关于我们
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
- 网站
-
http://www.nanoporetech.com
Oxford Nanopore Technologies的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Oxford
- 类型
- 上市公司
- 领域
- DNA sequencing和Next Generation Sequencing
地点
Oxford Nanopore Technologies员工
-
Bruce Ashford
Principal Linux Platform Engineer at Oxford Nanopore Technologies plc
-
Jordan Herman
SVP, General Counsel at Oxford Nanopore Technologies plc
-
Jonathan Ellard
Director, IT Programme Management at Oxford Nanopore Technologies Ltd
-
Roger Pettett
VP Informatics, Oxford Nanopore Technologies PLC
动态
-
Philipp Rescheneder and the rest of the Applications team at Oxford Nanopore Technologies are leading the charge in developing cutting-edge bioinformatics tools designed to maximise the potential of ultra-rich nanopore data. From supporting the creation of SV caller Sniffles, and germline somatic caller Severus, to unifying workflows with #EPI2ME to provide a holistic approach to reveal more biology. Interested in learning more about analysing the ultra-rich, data generated by #nanopore sequencing? Check out Philipp's blog to read more: https://bit.ly/3zaq8Tn Curious about how these innovations can elevate your research? Join us at NCM Boston to hear the latest from Philipp and his team during the Applications team's talk. Learn more: https://bit.ly/47bs9v9 #nanoporeconf #AnythingAnyoneAnywhere
Mining data-rich reads with Philipp Rescheneder
nanoporetech.com
-
There's only 48 hours left to get yourself a phase 4 ticket for NCM Boston! Check out what we have in store during our two innovation days, biopharma day and workshops. Ticket prices increase 1st September. Get yours now: https://bit.ly/4g5p6sv #nanoporeconf
-
-
Plasmidsaurus is setting a new standard by replacing traditional Sanger sequencing with nanopore technology. With over 500 global drop boxes, they’re delivering faster, more accurate plasmid verification — essential for gene therapy and microbial engineering. This blog showcases how nanopore sequencing overcomes challenges like GC-rich regions, complex repeats and the use of primers to offer a complete view of whole plasmids — all in a single read. Learn more: https://lnkd.in/egh65AVR
Plasmidsaurus redefine the gold standard: whole-plasmid sequencing with Oxford Nanopore
nanoporetech.com
-
Metagenomics offers the advantage of sequencing unculturable microbes and detecting elusive microorganisms that might otherwise be missed, providing a more comprehensive understanding of microbial diversity and its implications for health and disease. In this white paper, learn long nanopore reads provide greater resolution of mixed microbial samples, compared to other sequencing methods and how with real-time analysis nanopore technology provides a single platform for rapid identification and characterisation of any microbe. What you're missing matters. #WYMM Learn more https://bit.ly/4dP6yef
White paper: addressing the challenges of metagenomics with nanopore sequencing
nanoporetech.com
-
It was great to be part a productive week in Singapore, talking about the importance of diverse genomic datasets to improve health outcomes. Special thanks to High Commissioner Nikesh Mehta and UK in Singapore for hosting a brilliant evening that brought together leaders from across the region to promote the partnership in genomic medicine between the UK and Asia. We are inspired by the work going on in Singapore to advance understanding of the genetic diversity of multi-ethnic Asian populations, and we are proud to be part of it.
We just wrapped up a great week in Singapore at the PRECISE-IHCC conference, strengthening relationships with the vibrant genomic ecosystem here and celebrating Singapore’s efforts to advance understanding of the genetic diversity of its multi-ethnic Asian population through its landmark Precision Health Research, Singapore (PRECISE) project. At the conference, it was exciting to see genomic leaders from around the world explore the benefits of sequencing to support ageing populations through precision medicine and help prevent the next pandemic through rapid pathogen surveillance. So much can be enabled by genomic insights that reflect the world’s population. Oxford Nanopore was also delighted to support the ‘UK Asia Genomics Medicine Forum 2024’, hosted by British High Commissioner Nikesh Mehta to promote the partnership in genomic medicine between the UK and Asia. This brilliant evening bought together government representatives and key opinions leaders from across the region to discuss how we can collectively deepen our understanding of genomic data to identify the causes of disease – and development of new treatments. We are inspired by the work going on in Singapore and proud to be a part of it. Learn more about the PRECISE programme here: https://lnkd.in/eTKTrJMS
-
-
With just 3 weeks to go until NCM Boston 2024, make sure you secure a ticket before the final price increase on 1st September! Still unsure? Check out our agenda to discover the pioneering uses of #nanopore technology speakers will discuss, across an array of applications: https://bit.ly/4dskT0i
-
-
Biopharma quality controls (QC) are vital throughout the drug development pathway, yet current strategies require multiple, inefficient methods -— adding complexity and delaying turnaround time. In this brochure learn how #nanopore technology is enabling the delivery of rapid and comprehensive QC tests that could replace multiple legacy assays for faster access to robust results. Read here: https://bit.ly/3YObn3a
Biopharma — quality control
nanoporetech.com
-
A key part of Oxford Nanopore’s mission is to innovate our products to increase accessibility to the broader scientific community. 2023 saw us further implement this strategy by bringing solutions to the market through providing lower cost solutions, removing the need for centralised laboratories with our range of scalable devices and our development focuses on simplifying workflows so they can be used by a wider range of researchers. Read about the impact our products are having on the world’s greatest challenges in our FY 23 #sustainability report: https://bit.ly/4cdcCg8
-
-
Capturing disease-associated variants and epigenetic modifications across the entire genome is vital for effective clinical research. However, legacy sequencing technologies have restricted variant detection to regions that can be amplified, missing potential variants of interest. Furthermore, methylation must be indirectly detected via lengthy methods such as bisulfite conversion, giving incomplete results. In this workflow, discover how long, native #nanopore reads enable comprehensive, direct detection of single nucleotide variants (SNVs), structural variants (SVs), short tandem repeat (STR) expansions, and methylation across the human genome — all in a single sequencing run. Read here: https://bit.ly/46KtQjd
-